ArticleBMC gastroenterology2003
Analysis of antimicrobial susceptibility and virulence factors in Helicobacter pylori clinical isolates.
Article in BMC gastroenterology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 117 citations in OpenAlex.
- Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study.BMC gastroenterology · 2013Trial
- Efficacy of a 7-day course of furazolidone, levofloxacin, and lansoprazole after failed Helicobacter pylori eradication.BMC gastroenterology · 2009Trial
- Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease.World journal of gastroenterology · 2008Trial
- Furazolidone-based triple therapy for H pylori gastritis in children.World journal of gastroenterology · 2006Trial
- Efficacy of one-day quadruple therapy for H pylori infection in Chinese patients.World journal of gastroenterology · 2006Trial
- Effects of IntragastricJournal of clinical medicine · 2025Article
- Furazolidone susceptibility of Helicobacter pylori isolated from patients with gastroduodenal diseases in Colombia.Revista do Instituto de Medicina Tropical de Sao Paulo · 2025Article
- Effects ofFrontiers in cellular and infection microbiology · 2023Article
- Emergence of amoxicillin resistance and identification of novel mutations of the pbp1A gene in Helicobacter pylori in Vietnam.BMC microbiology · 2022Article
- Clarithromycin-resistant H. pylori primary strains and virulence genotypes in the Northeastern region of Brazil.Revista do Instituto de Medicina Tropical de Sao Paulo · 2022Article
- Article
- Investigation of Clarithromycin Resistance-Associated Mutations and Virulence Genotypes of Helicobacter pylori Isolated from Iranian Population: A Cross-Sectional Study.Current microbiology · 2021Article
- Should Networks Supplant Tree Building?Microorganisms · 2020Review
- Can bacterial virulence factors predict antibiotic resistantWorld journal of gastroenterology · 2018Article
- Phenotypic analysis of antibiotic resistance and genotypic study of theAntimicrobial resistance and infection control · 2018Article
- Resistance ofWorld journal of gastroenterology · 2017Article
- Prevalence of cytotoxin-associated genes ofGastroenterology and hepatology from bed to bench · 2017Article
- Antibiotic susceptibility, heteroresistance, and updated treatment strategies inDrug design, development and therapy · 2017Review
- Detection of Helicobacter pylori resistance to clarithromycin and fluoroquinolones in Brazil: A national survey.World journal of gastroenterology · 2016Observational
- Review article: the global emergence of Helicobacter pylori antibiotic resistance.Alimentary pharmacology & therapeutics · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn this study, we evaluated the prevalence of primary resistance of Brazilian H. pylori isolates to metronidazole, clarithromycin, amoxicillin, tetracycline, and furazolidone. In addition, the vacA, iceA, cagA and cagE genotypes of strains isolated from Brazilian patients were determined and associated with clinical data in an effort to correlate these four virulence markers and antibiotic resistance.
methodsH. pylori was cultured in 155 H. pylori-positive patients and MICs for metronidazole, clarithromycin, amoxicillin, tetracycline, and furazolidone were determined by the agar dilution method. Genomic DNA was extracted, and allelic variants of vacA, iceA, cagA and cagE were identified by the polymerase chain reaction.
resultsThere was a strong association between the vacA s1/cagA -positive genotype and peptic ulcer disease (OR = 5.42, 95% CI 2.6-11.3, p = 0.0006). Additionally, infection by more virulent strains may protect against GERD, since logistic regression showed a negative association between the more virulent strain, vacA s1/cagA-positive genotype and GERD (OR = 0.26, 95% CI 0.08-0.8, p = 0.03). Resistance to metronidazole was detected in 75 patients (55%), to amoxicillin in 54 individuals (38%), to clarithromycin in 23 patients (16%), to tetracycline in 13 patients (9%), and to furazolidone in 19 individuals (13%). No significant correlation between pathogenicity and resistance or susceptibility was detected when MIC values for each antibiotic were compared with different vacA, iceA, cagA and cagE genotypes.
conclusionThe analysis of virulence genes revealed a specific association between H. pylori strains and clinical outcome, furthermore, no significant association was detected among pathogenicity and resistance or susceptibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.